Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226286 · ClinicalTrials.gov registry record · NA
Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)
A NA study, sponsored by MedtronicNeuro.
- Completed
- Registry status
- NA
- Development phase
- 188
- Enrollment target
NCT05226286: Completed NA study, sponsored by MedtronicNeuro.
NCT05226286 is a NA study that has completed, run by MedtronicNeuro. The registered enrollment target is 188 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05226286, a NA study, has completed, sponsored by MedtronicNeuro.
- COMPLETED
- Registry status
- NA
- Development phase
- 188 participants
- Enrollment target
Study Summary
The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.
Primary Outcome
Proportion of TNM subjects experiencing a reduction of 50% or more in daily urinary urge incontinence (UUI) episodes (UUI responder rate) at 6 months after device implant.
Interventions
- DEVICE Medtronic Implantable Tibial Neuromodulation (TNM) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
What the finished NCT05226286 record still lists
NCT05226286 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Medtronic Implantable Tibial Neuromodulation (TNM) System is the first listed.
NCT05226286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05226286 about?
NCT05226286 is a clinical study titled "Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)". The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.
What is the current status of trial NCT05226286?
This trial is currently completed. It is a NA study. The enrollment target is 188 participants. The study started on 2022-01-31. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05226286?
The interventions under investigation include: Medtronic Implantable Tibial Neuromodulation (TNM) System (DEVICE).
Who is sponsoring clinical trial NCT05226286?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05226286's enrollment target sits among peer trials
188 576th of 2000 higher than 1,422 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI